PMID- 33402121
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan 5
TI  - Comparative efficacy and safety of adjuvant nivolumab versus other treatments in 
      adults with resected melanoma: a systematic literature review and network 
      meta-analysis.
PG  - 3
LID - 10.1186/s12885-020-07538-1 [doi]
LID - 3
AB  - BACKGROUND: Immune checkpoint inhibitors and targeted therapies are approved for 
      adjuvant treatment of patients with resected melanoma; however, they have not 
      been compared in randomized controlled trials (RCTs). We compared the efficacy 
      and safety of adjuvant nivolumab with other approved treatments using available 
      evidence from RCTs in a Bayesian network meta-analysis (NMA). METHODS: A 
      systematic literature review was conducted through May 2019 to identify relevant 
      RCTs evaluating approved adjuvant treatments. Outcomes of interest included 
      recurrence-free survival (RFS)/disease-free survival (DFS), distant 
      metastasis-free survival (DMFS), all-cause grade 3/4 adverse events (AEs), 
      discontinuations, and discontinuations due to AEs. Time-to-event outcomes 
      (RFS/DFS and DMFS) were analyzed both assuming that hazard ratios (HRs) are 
      constant over time and that they vary. RESULTS: Of 26 identified RCTs, 19 were 
      included in the NMA following a feasibility assessment. Based on HRs for RFS/DFS, 
      the risk of recurrence with nivolumab was similar to that of pembrolizumab and 
      lower than that of ipilimumab 3 mg/kg, ipilimumab 10 mg/kg, or interferon. Risk 
      of recurrence with nivolumab was similar to that of dabrafenib plus trametinib at 
      12 months, however, was lower beyond 12 months (HR [95% credible interval] at 
      24 months, 0.46 [0.27-0.78]; at 36 months, 0.28 [0.14-0.59]). Based on HRs for 
      DMFS, the risk of developing distant metastases was lower with nivolumab than 
      with ipilimumab 10 mg/kg or interferon and was similar to dabrafenib plus 
      trametinib. CONCLUSION: Adjuvant therapy with nivolumab provides an effective 
      treatment option with a promising risk-benefit profile.
FAU - Toor, Kabirraaj
AU  - Toor K
AD  - Precision HEOR, 1505 West 2nd Avenue, Vancouver, BC, V6H 3Y4, Canada. 
      kabirraaj.toor@precisionvh.com.
FAU - Middleton, Mark R
AU  - Middleton MR
AD  - University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, 
      OX3 7DQ, UK.
FAU - Chan, Keith
AU  - Chan K
AD  - Precision HEOR, 1505 West 2nd Avenue, Vancouver, BC, V6H 3Y4, Canada.
FAU - Amadi, Adenike
AU  - Amadi A
AD  - Bristol Myers Squibb, Unit 2 Uxbridge Business Park, Uxbridge, UB8 1DH, UK.
FAU - Moshyk, Andriy
AU  - Moshyk A
AD  - Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, 
      USA.
FAU - Kotapati, Srividya
AU  - Kotapati S
AD  - Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, 
      USA.
LA  - eng
GR  - Not applicable/Bristol-Myers Squibb Company/
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210105
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Imidazoles)
RN  - 0 (Ipilimumab)
RN  - 0 (Oximes)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 31YO63LBSN (Nivolumab)
RN  - 33E86K87QN (trametinib)
RN  - DPT0O3T46P (pembrolizumab)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bayes Theorem
MH  - Disease-Free Survival
MH  - Humans
MH  - Imidazoles/administration & dosage
MH  - Ipilimumab/administration & dosage
MH  - Melanoma/*drug therapy
MH  - Nivolumab/administration & dosage
MH  - Oximes/administration & dosage
MH  - Patient Safety
MH  - Pyridones/administration & dosage
MH  - Pyrimidinones/administration & dosage
PMC - PMC7784366
OTO - NOTNLM
OT  - Adjuvant treatment
OT  - Efficacy
OT  - Network meta-analysis
OT  - Nivolumab
OT  - Safety
OT  - Systematic literature review
COIS- KT and KC are employees of Precision HEOR, which received funding from Bristol 
      Myers Squibb for the current work. MRM has served as an advisor to Amgen, Array 
      Biopharma, BiolineRx, Bristol Myers Squibb, GlaxoSmithKline, Immunocore, Kineta, 
      Novartis, Rigontec, Roche, and Silicon Therapeutics; has received institutional 
      research support from Array Biopharma, AstraZeneca, BiolineRx, Bristol Myers 
      Squibb, Eisai, GlaxoSmithKline, Immunocore, Merck, Merck Sharp & Dohme, 
      Millenium, Novartis, Pfizer, Regeneron, Replimune, Rigontec, and Roche; has 
      received travel support from Immunocore, Merck, Merck Sharp & Dohme, and 
      Replimune; and is a member of an independent data safety monitoring committee for 
      Eisai and Merck/Merck Sharp & Dohme. AA and AM are employees of and stockholders 
      in Bristol Myers Squibb. SK is an employee of Bristol Myers Squibb.
EDAT- 2021/01/07 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/01/05
CRDT- 2021/01/06 05:29
PHST- 2020/07/02 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2021/01/06 05:29 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/01/05 00:00 [pmc-release]
AID - 10.1186/s12885-020-07538-1 [pii]
AID - 7538 [pii]
AID - 10.1186/s12885-020-07538-1 [doi]
PST - epublish
SO  - BMC Cancer. 2021 Jan 5;21(1):3. doi: 10.1186/s12885-020-07538-1.